1 Answers
Usual Adult Dose for Tuberculosis: Active:
15 to 30 mg/kg (up to 2 g) orally once a day in combination with three other antituberculous drugs for the initial 2 months of a 6-month or 9-month treatment regimen, until drug susceptibility tests are known. An alternate dosing regimen of 50 to 75 mg/kg (up to 3 g) orally twice a week may be used after 2 weeks of daily therapy to increase patient compliance.
Alternatively, the CDC, The American Thoracic Society, and the Infectious Diseases Society of America suggest the following dosing based on estimated lean body weight:
Daily dosing:
- 40 to 45 kg: 1000 mg
- 56 to 75 kg: 1500 mg
- 76 to 90 kg: 2000 mg
Twice weekly dosing:
- 40 to 55 kg: 2000 mg
- 56 to 75 kg: 3000 mg
- 76 to 90 kg: 4000 mg
Thrice weekly dosing:
- 40 to 55 kg: 1500 mg
- 56 to 75 kg: 2500 mg
- 76 to 90 kg: 3000 mg
Usual Adult Dose for Tuberculosis: Latent:
A public health expert should be consulted prior to the use of the combination regimen with rifampin.
15 to 20 mg/kg, based on actual body weight (lean), orally once daily (maximum 2 g) for 2 months. Alternatively, a dosage of 50 mg/kg may be administered orally twice-weekly (maximum 4 g).
Usual Pediatric Dose for Tuberculosis: Active:
(Used as part of a multidrug regimen. Treatment regimens consist of an initial 2-month phase, followed by a continuation phase of 4 or 7 additional months. Frequency of dosing may differ depending on phase of therapy)
Infants, Children less than 40 kg and Adolescents 14 years and younger and less than 40 kg:Non-HIV patients:
- Daily therapy: 15 to 30 mg/kg/dose (maximum: 2 g/dose) once daily
- Directly observed therapy (DOT): 50 mg/kg/dose (maximum: 2 g/dose) twice weekly
HIV-exposed/infected patients:
- Daily therapy: 20 to 40 mg/kg/dose once daily (maximum: 2 g/day)
Usage in Children: Pyrazinamide regimens employed in adults are probably equally effective in children. Pyrazinamide appears to be well tolerated in children.
Geriatric Use: Clinical studies of Pyrazinamide did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic or renal function, and of concomitant disease or other drug therapy.It does not appear that patients with impaired renal function require a reduction in dose. It may be prudent to select doses at the low end of the dosing range, however.
Renal Dose Adjustments: The manufacturer recommends to start therapy at low end of dosage range and monitor patient closely.For the treatment of active tuberculosis, the CDC, ATS, and IDSA recommend against daily dosing. For patients with CrCl less than 30 mL/min or patients receiving hemodialysis the recommended dose is 25 to 35 mg/kg per dose three times per week.
Liver Dose Adjustments: Monitor patients closely.
Dose Adjustments: In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic or renal function, and of concomitant disease or other drug therapy.
If organism is susceptible to isoniazid and rifampin, pyrazinamide is continued for the first 2 months of a 6-month course of therapy (9-months if HIV positive). If primary drug resistance is shown, drug regimens should be adjusted as needed and continued for at least 6 months, or 3 months beyond culture conversion (9 months, or 6 months beyond culture conversion if HIV positive). If multiple-drug resistance is demonstrated, therapy should be continued for 12 to 24 months following culture conversion.
ফিরিজিন ট্যাবলেট সম্পর্কে বিস্তারিত জেনে নিন এই লিঙ্ক থেকে ফিরিজিন